News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Video: Patent Battle Over CRISPR Gene Editing
Jef Akst | Dec 13, 2016
goes to court for a CRISPR patent interference case at the US Patent and Trademark Office.
New Developments in CRISPR Patent Case
Jef Akst | Dec 12, 2016
Documents suggest Feng Zhang started working on CRISPR before Jennifer Doudna’s group published; researchers call for CRISPR technology to be shared openly
CRISPR Oral Arguments Recap, Cont’d
Jef Akst | Dec 8, 2016
This week’s CRISPR patent hearing took a deep dive into the science of moving the gene-editing technology from prokaryotes to eukaryotic systems.
USPTO to Hear Arguments on CRISPR Patents
Jef Akst | Dec 5, 2016
Tuesday morning, the US Patent and Trademark Office will hear oral arguments from the two parties that claim to have been the first to use CRISPR-Cas9 gene editing technology in eukaryotic cells.
Week in Review: August 29–September 2
Jef Akst | Sep 2, 2016
Roger Tsien dies; the CRISPR patent dispute you’ve never heard of; immunotherapy for Alzheimer’s; Tasmanian devils developing resistance to transmissible cancer
Student Alleges His Team Didn’t Earn CRISPR Patent
Kerry Grens | Aug 18, 2016
A former researcher at the Broad Institute has suggested the University of California, Berkeley, team deserves credit for inventing the gene-editing technique.
Do Patents Promote or Stall Innovation?
Catherine Offord | Jun 1, 2016
A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.
CRISPR Patent Investigation to Begin
Jef Akst | Mar 9, 2016
The US Patent and Trademark Office is set to launch its “patent interference” inquiry into the competing patents on the gene-editing technology.
New CRISPR Patent Issued
Jef Akst | Feb 18, 2016
Caribou Biosciences receives a patent related to the gene-editing technology.
Who Owns CRISPR?
Jenny Rood | Apr 3, 2015
With one US patent awarded and many other applications under consideration for the popular genome-editing technology, companies are adopting multiple strategies to navigate the complex intellectual property landscape.